

## Pennine MSK Rheumatoid Arthritis Care Pathway

**Refer to Pennine MSK Partnership for urgent specialist review**  
if persistent synovitis of undetermined cause involving small joints of the hands or feet/  
more than one joint is affected or there has been a delay from onset of symptoms => 3  
months <https://www.nice.org.uk/guidance/ng100/chapter/Recommendations#referral-from-primary-care>

**Triage for review by GPwSI/ Consultant Rheumatologist within 3/52**  
Musculoskeletal examination & any outstanding investigations:  
FBC, ESR, U&Es, LFTs, RF, ANA (consider anti-CCP if RF -ve)  
XRs chest, hands & feet; US only if synovitis =<1 joint & sub-clinical disease suspected  
Review analgesia/ use of NSAIDs  
IM/ IAJ/ oral corticosteroids as appropriate  
Commence Methotrexate or Sulfasalazine as soon as possible unless contraindicated or  
Hydroxychloroquine if mild / palindromic disease  
Invite to participate in National Early Inflammatory Arthritis Audit

**Review by rheumatologist within 2/52 if RA suspected**  
Baseline disease activity assessment (DAS)  
IM/ IAJ/ oral corticosteroids according to PGDs  
Information regarding diagnosis & treatment route

**Consultant or Independent nurse prescriber review**  
if DAS > 3.2 despite optimal treatment or  
if side effects / intolerance  
or extra-articular disease/co-morbidities detected

**Undertake biologic screening & refer virtual biologics clinic**  
if DAS >5.1 & failed combination therapy

**Consider dose tapering** or stopping drugs in a step down strategy for patients in remission or low disease activity

**Nurse led care if RA confirmed**  
Patient education  
Shared clinical decision-making  
Shared care monitoring with GP according to DMARD protocols  
DMARD initiations as recommended by a prescriber  
Dose titration according to nurse led dose titration protocols  
IM/ IAJ/ oral corticosteroids according to PGDs  
Offer review 4-6 weekly until DAS <3.2 or disease well controlled (< 3 swollen joints)  
If DAS < 3.2, review 3-6 monthly  
If disease stable for 12 months, annual review as per NICE guidance  
<https://www.nice.org.uk/guidance/ng100/chapter/Recommendations>  
Including assessment of disease progression (DAS53, x-rays hands & feet for progression or ultrasound if indicated), MSKHQ, cardiovascular risk (Eular guidelines); osteoporosis screen (FRAX); identify depression

**Ongoing support for self care**  
Advice line access  
Social prescribing referrals e.g. Early Help; NRAS; Working Well programme; OCL; Smoking cessation service; Mind

**MDT referrals as appropriate**  
e.g. OT; physiotherapy; podiatry; psychology; social work; dietician

**Referral to orthopaedic surgeon**  
if irreversible damage unresponsive to conservative treatment